Cargando…

Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients

Detalles Bibliográficos
Autores principales:	M, Montero-Baladía, L, Buzón, I, Astigarraga, P, Delgado, E, Iglesias, F, Callejo, M, López-Veloso, J, Minguito, M, Fernández-Regueras, M, Ubeira, G, Hermida
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306195/ https://www.ncbi.nlm.nih.gov/pubmed/32579985 http://dx.doi.org/10.1016/j.jinf.2020.06.006

Ejemplares similares

Etoposide for Cytokine Storm Because of Coronavirus Disease 2019
por: Delgado-López, Pedro David, et al.
Publicado: (2021)

High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients
por: Iglesias-Julián, Enrique, et al.
Publicado: (2020)

Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients
por: Luis, Buzon-Martín, et al.
Publicado: (2021)

Critically Ill Immunosuppressed Host
por: Masur, Henry
Publicado: (2008)

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
por: de Jong, R. S., et al.
Publicado: (1997)

Chronic Critical Illness and the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome
por: Hawkins, Russell B., et al.
Publicado: (2018)

Influenza and associated co-infections in critically ill immunosuppressed patients
por: Martin-Loeches, Ignacio, et al.
Publicado: (2019)

Copper as a potential adjunct therapy for critically ill COVID-19 patients
por: Fooladi, Shahnaz, et al.
Publicado: (2020)

Effectiveness of adjunctive nebulized antibiotics in critically ill patients with respiratory tract infections
por: Leache, Leire, et al.
Publicado: (2019)

The AI-discovered aetiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients
Publicado: (2020)

Case Report: Successful Treatment of Five Critically Ill Coronavirus Disease 2019 Patients Using Combination Therapy With Etoposide and Corticosteroids
por: Aoyagi, Tetsuji, et al.
Publicado: (2021)

Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile.
por: de Jong, R. S., et al.
Publicado: (1997)

Biodistribution of etoposide via intratumoral chemotherapy with etoposide-loaded implants
por: Wu, Chunsheng, et al.
Publicado: (2020)

Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study
por: Doshi, Neha M, et al.
Publicado: (2013)

Evidence‐based rationale for low dose nivolumab in critically ill patients with sepsis‐induced immunosuppression
por: van den Haak, Demy A. C., et al.
Publicado: (2023)

Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide
por: Siderov, J, et al.
Publicado: (2002)

Lymphocyte HVEM/BTLA co-expression after critical illness demonstrates severity indiscriminate upregulation, impacting critical illness-induced immunosuppression
por: Wakeley, Michelle E., et al.
Publicado: (2023)

Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study
por: Al Sulaiman, Khalid, et al.
Publicado: (2021)

The effect of etoposide on human CFU-GM.
por: Bailey-Wood, R., et al.
Publicado: (1985)

Molecular mechanisms of etoposide
por: Montecucco, Alessandra, et al.
Publicado: (2015)

Prognostic Value of Immunosuppressive Acidic Protein and Oxidative Stress Status in Critically Ill Patients
por: Tutuncu, Elif O, et al.
Publicado: (2021)

Radiographic assessment of photodynamic therapy as an adjunctive treatment on induced periodontitis in immunosuppressed rats
por: FERNANDES, Leandro Araújo, et al.
Publicado: (2010)

Predictors of in-hospital mortality in critically ill patients with secondary and tertiary peritonitis
por: Ballús Noguera, J, et al.
Publicado: (2015)

Adjunctive Therapies During Extracorporeal Membrane Oxygenation to Enhance Multiple Organ Support in Critically Ill Children
por: Canter, Marguerite Orsi, et al.
Publicado: (2018)

Practice of adjunctive treatments in critically ill COVID–19 patients—rational for the multicenter observational PRoAcT-COVID study in The Netherlands
por: Valk, Christel M. A., et al.
Publicado: (2021)

Reduced Monocytic Human Leukocyte Antigen-DR Expression Indicates Immunosuppression in Critically Ill COVID-19 Patients
por: Spinetti, Thibaud, et al.
Publicado: (2020)

The potential role of adjunctive ascorbic acid in the prevention of colistin-induced nephrotoxicity in critically ill patients: A retrospective study
por: Al Sulaiman, Khalid, et al.
Publicado: (2022)

Field evaluation of the enhanced MM3-COPRO ELISA test for the diagnosis of Fasciola hepatica infection in sheep
por: Mezo, Mercedes, et al.
Publicado: (2022)

Are Steroids a Beneficial Adjunctive Therapy in the Immunosuppressed Patient with Herpes Simplex Virus Encephalitis?
por: Lizarraga, Karlo J., et al.
Publicado: (2013)

Author Correction: Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study
por: Al Sulaiman, Khalid, et al.
Publicado: (2021)

Adjunctive ketamine for sedation in critically ill mechanically ventilated patients: an active-controlled, pilot, feasibility clinical trial
por: Amer, Marwa, et al.
Publicado: (2021)

Recurrent Metastatic Choriocarcinoma Responsive to Etoposide and Cisplatin with Etoposide, Methotrexate, and Dactinomycin: A Case Report
por: Das, Sunil Kumar, et al.
Publicado: (2022)

Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study
por: Al Sulaiman, Khalid, et al.
Publicado: (2021)

Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort study
por: Martín, Luis Buzón, et al.
Publicado: (2019)

Adjunctive therapy for severe malaria: a review and critical appraisal
por: Varo, Rosauro, et al.
Publicado: (2018)

Molecular determinants of etoposide resistance in HL60 cells
por: Alghamdi, Rasha H, et al.
Publicado: (2022)

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
por: Mitry, E, et al.
Publicado: (1999)

Risk Factors for Fungal Co-Infections in Critically Ill COVID-19 Patients, with a Focus on Immunosuppressants
por: Ezeokoli, Obinna T., et al.
Publicado: (2021)

The role of etoposide in the treatment of adult patients with hemophagocytic lymphohistiocytosis
por: Zondag, Timo C. E., et al.
Publicado: (2023)

The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide.
por: Harvey, V. J., et al.
Publicado: (1985)

Cannot write session to /tmp/vufind_sessions/sess_2ru8l4amvg279biojqp04sgcoi